The Magnis BR was successful in spawning a novel in-hospital channel in China. Currently, the system has been deployed to over 50 hospitals across 13 provinces in the country. The impact of the Magnis is multifaceted and has set the stage for a wide range of changes from both a regulatory and an overall business model perspective. For hospitals, the adoption of the system allows these healthcare institutions to become partners by generating revenue for their testing services. Additionally, the ease of deployment of the Magnis BR allowed for a widening of access to NGS testing in more rural or historically underserved communities, that might not have the capability of internally developing and validating LDTs. Historically, patients who live in rural settings have had disproportionately less access to genetic testing as most clinical studies tend to favor the inclusion of patients that live near large metropolitan cities. The development of IVD systems, like the Magnis BR, that enable numerous laboratory sites to participate in large scale studies could be a large step in ensuring patients of all socioeconomic backgrounds are accounted for in future clinical studies. Additionally, less funded hospitals have historically had issues creating independent bioinformatic pipelines. The incorporation of the Magnis BR system served to standardize the process for data collection across dozens of hospitals, allowing for the generation of meta-data that can further refine a single powerful pipeline. This will in turn result in greater consistency in the therapeutic decision-making process through more accurate molecular characterization due to the standardization of diagnostic criteria.